Efficacy of Autologous Platelet-Rich Plasma alone or in Combination with a Lotion Containing Growth-Factor like Polypeptides and Taurine in the Treatment of Androgenic Alopecia: A Randomized, Prospective, Assessor-Blinded Trial

Tiziana Lazzari1, Massimo Milani2*

1Dermatology Clinic, Montallegro, Italy; 2Medical Department, Cantabria Labs Difa Cooper, Caronno Pertusella, Italy

ABSTRACT
Introduction and Objectives: Autologous Platelet-Rich Plasma (PRP) dermal injections are considered as a therapeutic option for the medical treatment of androgenic alopecia (AGA). However, clinical efficacy of this approach in some cases could be disappointing. Positive effects of PRP in AGA seem to correlate, at least in part, with a growth factors mimicking action. A hair scalp lotion containing high-purified, growth factors-like polypeptides (octapeptide 2, acetyl decapeptide 3, oligopeptide 20 and copper tripeptide) with the addition of glycine and taurine (GFM-L) is available. So far, no data regarding the potential synergistic effect of autologous PRP treatment combined with GFM-L are available.

We therefore conducted a prospective, randomized, assessor-blinded trial to compare the efficacy and tolerability of PRP alone vs. PRP and GFM-L treatment in men and women with AGA.

Materials and Methods: The study was a prospective, randomized (with a balance ratio of 2:1), assessor-blinded, 3-month trial. Thirty subjects (18 men and 12 women; mean age: 41 years) were enrolled after their written informed consent. Twenty subjects were allocated to PRP treatment cycle followed by GFM-L application for 3 months (2 ml of lotion every other day) (Group A) and 10 subjects were allocated to PRP treatment alone (Group B).

In both groups autologous PRP injections on the affected area were performed over a period of 3 months at interval of 3-4 weeks, using a volume of 10 cc of PRP for each session treatment. Primary end point was the Investigator Global Assessment (IGA) score of clinical efficacy at month 3 in comparison with baseline.

IGA score ranged from 0 (no improvement) to 3 (strong improvement). Secondary endpoint was the evolution of Hamilton scale grading (HSG), evaluated at baseline and at the end of study period. IGA score and HSG were performed by an investigator unaware of the treatment allocation group.

Results: All the enrolled subjects concluded the study period. At baseline HSG was 2.0 ± 0.6 in Group A and 2.1 ± 0.3 in Group B. At month 3, a significant reduction of HSG was observed in Group A subjects only, both in comparison with baseline and in comparison, with Group B values (1.3 ± 0.5 vs. 2.1 ± 0.37; P=0.0028). At month 3, IGA score was 2.1 ± 0.9 in group A and 0.8 ± 0.3 in group B (P=0.0031). GFM-lotion was well tolerated.

Conclusion: The combination of GFM-lotion containing growth factors like peptides and taurine with autologous PRP treatment is superior in term of efficacy to the treatment with PRP alone in subjects with AGA.

Keywords: Androgenic alopecia; Platelet-rich-plasma; Growth factor; Controlled trial

*Correspondence to: Massimo Milani, Medical Department, Cantabria Labs Difa Cooper, Caronno Pertusella, Italy, Tel: +39029659031; E-mail: massimo.milani@difacooper.com

Received: September 06, 2019; Accepted: September 16, 2019; Published: September 24, 2019

Citation: Lazzari T, Milani M (2019). Efficacy of Autologous Platelet-Rich Plasma alone or in Combination with a Lotion Containing Growth-Factor like Polypeptides and Taurine in the Treatment of Androgenic Alopecia: A Randomized, Prospective, Assessor-Blinded Trial. J Clin Exp Dermatol Res. 10:506. DOI: 10.35248/2155-9554.19.10.506

Copyright: © 2019 Lazzari T. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

J Clin Exp Dermatol Res, Vol.10 Iss.5 No:1000506
INTRODUCTION

Androgenic alopecia (AGA) (also known as pattern alopecia) is the most common form a chronic non-scarring hair loss, affecting both men and women [1]. AGA is characterized by progressive hair loss, especially of scalp hair, and has distinctive patterns of loss in women versus men, but in both genders the central scalp is most severely affected [2].

Follicular miniaturization and local high dihydrotestosterone (DHT) activity are considered the main pathological mechanisms involved in AGA [3]. Microinflammation is also a relevant pathogenetic mechanism involved in this clinical condition [4].

Approved therapeutic options are limited to topical minoxidil [5] for both men and women and oral finasteride [6] for men. However, both drugs possess side effects and are effective in less than 50% of treated patients [7].

Autologous Platelet-Rich Plasma (PRP) dermal injection is an additional therapeutic option for the medical treatment of AGA [8]. However, clinical efficacy of this approach in some cases could be disappointing [9]. Positive effects of PRP in AGA seem correlated, at least in part, with a growth factors mimicking action [10].

PRP is rich in growth factors like PDGF (platelet derived growth factor), TGF (transforming growth Factor Beta) and VEGF (Vascular endothelial growth Factor) [11]. A hair scalp lotion containing high-purified, growth factors-like polypeptides (octapeptide 2, acetyl decapeptide 3, oligopeptide 20 and copper tripeptide) with the addition of glycine and taurine (GFML) is available.

Copper tripeptide has shown to have antioxidant [12], anti-inflammatory and blood vessel growth promoting action [13]. Copper tripeptide can increase the activity of FGF (Fibroblast Growth Factor) and VEGF [14]. Interestingly, copper tripeptide decreases the secretion of TGF-β [15] from dermal fibroblasts. TGF-β is involved in inducing catagen phase [16].

Copper tripeptide can also interfere with the activity of 5α-reductase, therefore reducing the production of DHT [17]. Finally, this peptide is also able to stimulate the production of decorin [18].

Decorin, at scalp level, improves the anagen phase [19] and consequently hair growth [20]. The acetyl decapeptide is a synthetic peptide that mimics the action of two growth factors: the keratinocyte growth factor (KGF) and the epidermal growth factor (EGF), which acts on the follicle, promoting the anagen growth phase, through an antiapoptotic effect [21], maintaining the bulge stem cells active [22].

Another component of the growth factor like mixture, octapeptide 2, is able to promote hair growth [23], to reduce apoptosis and to increase keratinocyte proliferation [24].

In this formulation all the 4 oligopeptides are vehiculated in nanosomes of 250 nm in diameter. Published data state that nanosomes with a diameter<500 nm can transport molecules deep in the hair bulb, after topical application [25].

Taurine is a relevant amino acid with interesting hair growth promoting mechanisms [26]. This lotion has shown to be effective as stand-alone approach in the treatment of excessive hair loss in men and women [27].

The peculiar composition of this lotion (mixture of growth factor like peptides and taurine) suggests a potential synergistic effect on hair growth with other therapeutic strategies like PRP treatment. So far, no data regarding the potential synergistic effect of autologous PRP treatment combined with GFML are available.

We therefore conducted a prospective, randomized, assessor-blinded trial to compare the efficacy and tolerability of PRP alone vs. PRP and GFML treatment in men and women with AGA.

STUDY AIM

We conducted a prospective, randomized, assessor-blinded, monocenter trial to evaluate and compare the potential additional clinical effect of a lotion containing a growth-factor like mixture and taurine (GFML) in subjects with AGA treated with PRP.

SUBJECTS AND METHODS

Study design

The clinical setting was the Dermatology and Hair pathology Unit outpatient service at the Montallergo Hospital; Genoa (Italy). The local IRB approved the study protocol in April 2018. The trial was conducted according to Good Clinical Practice Guidelines and Helsinki Declaration (update 2014) [28]. There was no change to the trial protocol after it commenced.

The study took place from June 2018 and March 2019. The study was a prospective, randomized (with a balance ratio of 2:1), assessor-blinded, 3-month trial. For allocation of the participants, a computer-generated list of random numbers was used.

Subjects

Eligible subjects included men and women aged ≥ 18 years with a diagnosis of AGA, suitable for a Platelet Rich Plasma (PRP) treatment. Exclusion criteria were other forms of hair loss, dermatitis of the scalp and a positive history of allergy or intolerance with one or more components of the tested lotion, pregnancy or breast feeding.

Thirty subjects (18 men and 12 women; mean age: 41 years) were enrolled in the trial after their written informed consent. For both groups, autologous PRP injections on the affected area were performed over a period of 3 months at interval of 3 weeks, using a volume of 10 cc of PRP for each session treatment.

In total 4 PRP injections were performed in each enrolled subject. In group A the GFML was applied using the dosage of 2 ml every other day for a total of 3 months.
Study outcomes

Primary end point of the trial was the Investigator Global Assessment (IGA) score of clinical efficacy at month 3 in comparison with baseline. IGA score ranged from 0 (no improvement) to 3 (strong improvement).

Secondary endpoint was the evolution of Hamilton scale grading (HSG), evaluated at baseline and at the end of study period. IGA score and HSG were performed by an investigator unaware of the treatment group (PRP alone vs. PRP and GFM-L).

Statistical analysis

Statistical analysis was performed using GraphPad Statistical Software (GraphPad Software, Inc., La Jolla, CA, USA). Continuous variables were expressed as mean ± standard deviation (SD). The primary outcomes of the study to evaluate and compare the evolution of IGA score.

For inferential statistical analysis we use the ANOVA multiple comparison test and the Paired Student T Test. We calculated also the 95% Confidence Intervals (CI) of the difference in all the variables evaluated.

This was a superiority trial. Sample size calculation was performed calculating the hypothesized difference in IGA score between the two groups (A and B) at end of the treatment: with an effect size (Cohen’s d value) of 0.38, with an alpha value of 0.05 and a power of 80% a total of at least 30 subjects should be enrolled to detect this difference.

The sample size was calculated using G-Power statistical software version 3.9 (Kiel, Germany). A p-value of <.05 was considered as significant. Analysis was performed based on intention-to-treat (ITT) principle.

RESULTS

A total of 30 subjects were enrolled in the trial. Twenty subjects were allocated to PRP treatment followed by GFM-L application for 3 months (Group A) and 10 subjects were allocated to PRP treatment alone (Group B). At baseline HSG was 2.0 ± 0.6 in Group A and 2.1 ± 0.3 in Group B. All the enrolled subjects concluded the trial. In comparison to group B, group A showed a greater increase of IGA score and a more pronounced reduction in HSG.

At month 3, IGA score was 2.1 ± 0.9 in group A and 0.8 ± 0.3 in group B (P=0.0031) (Figure 1) with an absolute difference of 1.3 (95% CI: from 2 to 0.5).

At month 3, a significant reduction of HSG was observed in Group A subjects only, both in comparison with baseline values and in comparison with Group B values (1.3 ± 0.5 vs. 2.1 ± 0.37; P=0.0028) with an absolute difference of -0.7 (95% CI: from -1.1 to -0.2) (Figure 2).

Figure 3 shows the scalp pictures of three enrolled subjects at baseline and after treatment, (two in the group A and one in group B). GFM-lotion was well tolerated. No serious side effects were reported.

Figure 1: IGA score at the end of 3 months treatment. *p=0.0031 Group A vs. Group B.

Figure 2: Hamilton Scale Grading at baseline and at the end of 3 months treatments. *p=0.001 Group A month 3 vs. Group A baseline; **p=0.0028 Group A month 3 vs. Group B month 3.
DISCUSSION

AGA is a very common hair disorder with a relevant impact on quality of life [29]. Oral finasteride and topical minoxidil are the only two drugs approved for the treatment of AGA [30]. Both drugs, however, possess side effects [31] and are effective in less than 50% of treated patients [32]. PRP is considered an alternative therapeutic approach for AGA [33]. PRP is an autologous preparation of plasma with platelets that are capable of secreting growth factors and cytokines, which stimulate stem cells [34]. The stimulatory factors in PRP, including fibrin, fibronectin and vitronectin, may be involved in hair follicle growth and development [35]. PRP contains a mixture of growth factors molecules such as PDGF, IGF and VEGF [36]. However, the results of studies on the use of PRP in AGA treatment remain controversial [37]. PRP contains also TGF-β which could have a detrimental effect on hair growth [9], promoting the catagen phase and fibrotic processes. Rodrigues has shown that efficacy of PRP in AGA seems do not correlate with the amount of the most common growth factors present in the PRP preparation, suggesting that the efficacy could be, at least in part, ascribed to additional mechanisms of action [38]. In this trial we demonstrated that the addition of a lotion containing a
Collins et al. have demonstrated that taurine blocks the nanosomes, and taurine significantly increase the clinical effect of PRP treatment in subjects with AGA. The complex of growth-factor like polypeptides, present in the tested lotion, contains copper-tripeptide, octapeptide 2, acetyl-decapeptide and oligopeptide 20. Copper tripeptide is able to increase the activity of FGF and VEGF and it also has a potent anti-oxidant and anti-inflammatory effect. Octapeptide 2, known also as pro-hairin, can increase the hair growth rate, probably increasing the anagen phase, to reduce apoptosis and to increase keratinocyte proliferation. Oligopeptide 20 can increase the insulin-like growth factor (IGF-1) production. IGF-1 produced by the mesenchymal cells, is an important growth factor in different biological systems: at the level of the hair follicle, it is produced by the dermal papilla and has the function of promoting the duration of the anagen. This lotion contains also taurine. This amino acid has several positive effects on hair bulb and hair growth. These active components of the GFM-L are conveyed in nanosomes, which allow the rapid absorption and a deep release into the follicle. The nanosomes are small micelles within which are enclosed substances to be conducted at depths up to the follicular matrix and bulge, protecting them by the action of the endogenous protease during penetration. Therefore, the composition and the formulation of this lotion (mixture of growth-factor like peptides in nanosomes and taurine) suggest a potential synergistic effect on hair growth with other therapeutic strategies like PRP treatment. The results of our study seem to confirm this hypothesis. At the moment is difficult to explain the mechanism of this additive clinical effect. The combined use of this lotion in subjects treated with PRP can amplify the growth hair stimulus but also counteract some negative actions on hair physiology of some components of PRP for example the TGF-β. Collins et al. have demonstrated that taurine blocks the deleterious effect of TGF-β on human hair follicle. Some limitations should be taken in account in evaluating our results. First, this trial was not a double-blind study. To increase the internal validity of the trial results, we decided to adopt an assessor-blinded approach in evaluating the main clinical efficacy outcomes of the study (evolution of IGA score). Another limit of the present trial is the relatively small sample size (30 patients in total). However, taking in account previous trials, we have performed an accurate sample size calculation which justifies the number of subjects we have enrolled in the trial.

**CONCLUSION**

The combination of GFM-lotion containing growth factors like peptides and taurine with autologous PRP treatment is superior in term of clinical efficacy to the treatment with PRP alone in subjects with AGA.

**ACKNOWLEDGEMENT**

MM is an employee of Cantabria Labs Difa Cooper; a pharma company, producing and marketing the tested product (GFM™ Cantabria Labs Difa Cooper). MM participated to the study protocol preparation and was involved in the final version of the manuscript. MM was not involved in data analysis and statistical evaluation. TL was involved in the conduction of the trial (selection of subjects, visits, medical evaluation, data collection, and picture coding and data analysis).

**REFERENCES**

1. Sinclair R. Male pattern androgenetic alopecia. Bmj. 1998; 317: 865-869.
2. Lolli F, Pallotti F, Rossi A, Fortuna MC, Caro G, Lenzi A, et al. Androgenetic alopecia: A review. Endocrine. 2017; 57: 9-17.
3. Ellis JA, Sinclair R, Harrap SB. Androgenetic alopecia: Pathogenesis and potential for therapy. Expert reviews in molecular medicine. 2002; 4: 1-11.
4. Mahé YF, Michelet JF, Billoni N, Jarrousse F, Buan B, Bernard BA, et al. Androgenetic alopecia and microinflammation. Int J Dermatol. 2000; 39: 576-584.
5. Price VH. Treatment of hair loss. N Engl J Med. 1999; 341: 964-973.
6. Mella JM, Perret MC, Manzotti M, Catalano HN, Guyart G. Efficacy and safety of finasteride therapy for androgenetic alopecia: A systematic review. Arch Dermatol. 2010; 146: 1141-1150.
7. Adil A, Godwin M. The effectiveness of treatments for androgenetic alopecia: A systematic review and meta-analysis. J Am Acad Dermatol. 2017; 77: 136-141.
8. Gkini MA, Kouskoukis AE, Tripiani G, Rigopoulos D, Kouskoukis K. Study of platelet-rich plasma injections in the treatment of androgenetic alopecia through an one-year period. J Cutan Aesthet Surg. 2014; 7: 213.
9. Khatu SS, More YE, Gokhale NR, Chavan DC, Bendsure N. Platelet-rich plasma in androgenic alopecia: myth or an effective tool. Journal of cutaneous and aesthetic surgery. 2014; 7: 107.
10. Li ZJ, Choi HI, Choi DK, Sohn KC, Im M, See YJ, et al. Autologous platelet-rich plasma: A potential therapeutic tool for promoting hair growth. Dermatol Surg. 2012; 38: 1040-1046.
11. Sundman EA, Cole BJ, Fortier LA. Growth factor and catabolic cytokine concentrations are influenced by the cellular composition of platelet-rich plasma. Am J Sports Med. 2011; 39: 2135-2140.
12. Pickart L, Vasquez-Soltero JM, Margolina A. The human tripeptide GHK-Cu in prevention of oxidative stress and degenerative conditions of aging: Implications for cognitive health. Oxid Med Cell Longev. 2012; 324832.
13. Hostynnek JJ, Dreher F, Maibaum HI. Human skin retention and penetration of a copper tripeptide in vitro as function of skin layer towards anti-inflammatory therapy. Inflamm Res. 2010; 59: 983-988.
14. Pollard JD, Quan S, Kang T, Koch RJ. Effects of copper tripeptide on the growth and expression of growth factors by normal and irradiated fibroblasts. Arch Facial Plast Surg. 2005; 7: 27-31.
15. McCormack MC, Nowak KC, Koch RJ. The effect of copper tripeptide and tretinoin on growth factor production in a serum-free fibroblast model. Arch Facial Plast Surg. 2001; 3: 28-32.
16. Soma T, Tsuji Y, Hibino T. Involvement of transforming growth factor-β2 in catagen induction during the human hair cycle. J Invest Dermatol. 2002; 118: 993-997.
17. Kaliyadan F, Nambari A, Vijayaraghavan S. Androgenetic alopecia: An update. Indian J Dermatol Venerol Leprol. 2013; 79: 613.
18. Wegrowski Y, Mazaert FX, Borel JP. Stimulation of sulfated glycosaminoglycan synthesis by the tripeptide-copper complex glycyyl-L-histidyl-L-lysine-Cu2+. Life Sciences. 1992; 51: 1049-1056.
19. Jing J, Wu XJ, Li YL, Cai SQ, Zheng M, Lu ZF. Expression of decorin throughout the murine hair follicle cycle: hair cycle dependence and anagen phase prolongation. Exp Dermatol. 2014; 23: 486-491.
20. Inui S, Itami S. A newly discovered linkage between proteoglycans and hair biology: Decorin acts as an anagen inducer. Exp Dermatol. 2014; 23: 547-548.

21. Braun S, Krampert M, Bodó E, Künmin A, Born-Berclaz C, Paus R, et al. Keratinocyte growth factor protects epidermis and hair follicles from cell death induced by UV irradiation, chemotherapeutic or cytotoxic agents. J Cell Sci. 2006; 119: 4841-4849.

22. Zhang X. Maintenance of high proliferation and multipotent potential of human hair follicle-derived mesenchymal stem cells by growth factors. Int J Mol Med. 2013; 31: 913-921.

23. Ji CY, Deug KY, Ryul KC. Peptides for promoting hair growth and improving wrinkle and cosmetic compositions comprising the same. US Patent. 2012; 8: 106.

24. Debraj S, Rinky K. Composition and method for an intradermal hair growth solution. US Patent No 9. 2017; 700:504.

25. Rancan F, Afraz Z, Combadiere B, Peytavi UB, Vogt A. Hair follicle targeting with nanoparticles. Nanotechnol Dermatol. 2013; 95-107.

26. Collin C, Gautier B, Gaillard O, Hallegot P, Chabane S, Bastien, P, et al. Protective effects of taurine on human hair follicle grown in vitro. Int J Cosmet Sci. 2006; 28: 289-298.

27. Piraccini BM, Starace M, Guerrera M, Burroni AG, De Col E, Fabbrocini G, et al. The growth factors in the treatment of hair loss: Results of a multicenter study. Il Punto in Dermatologia. 2014; 1:10.

28. Declaration H. World Medical Association Declaration of Helsinki. 2014.

29. Han SH, Byun JW, Lee WS, Kang H, Kye YC, Kim KH, et al. Quality of life assessment in male patients with androgenetic alopecia: Result of a prospective, multicenter study. Annals of dermatology. 2012; 24: 311-318.

30. Orberg N, Finner AM, Shapiro J. Androgenetic alopecia. Endocrinology and metabolism clinics of North America. 2007; 36: 379-398.

31. Irwig MS, Kolukula S. Persistent sexual side effects of finasteride for male pattern hair loss. J Sex Med. 2011; 8: 1747-1753.

32. McElwee KJ, Shapiro JS. Promising therapies for treating and/or preventing androgenic alopecia. Skin Therapy Lett. 2012; 17: 1-4.

33. Giordano S, Romeo M, Lankinen P. Platelet-rich plasma for androgenetic alopecia: Does it work? Evidence from meta-analysis. J Cosmet Dermatol. 2017, 16: 374-381.

34. Bendinelli P, Marteucci E, Dogliotti G, Corsi MM, Banfi G, Maroni P, et al. Molecular basis of anti-inflammatory activity of platelet-rich plasma on human chondrocytes: Mechanisms of NF-κB inhibition via HGF. J Cell Physiol. 2010; 225: 757-766.

35. Marx RE. Platelet-Rich Plasma (PRP): What is PRP and what is not PRP? Implant Dent. 2001; 10: 225-228.

36. Eppley BL, Woodell JE, Higgins J. Platelet quantification and growth factor analysis from platelet-rich plasma: Implications for wound healing. Plast Reconstr Surg. 2004; 114: 1502-1508.

37. Botchkareva NV, Ahluwalia G, Shander D. Apoptosis in the hair follicle. J Invest Dermatol. 2006; 126: 258-264.

38. Rodrigues BL, Montalvão SA, Cancela RB, Silva FA, Urban A, Huber SC, et al. Treatment of male pattern alopecia with platelet-rich plasma: A double-blind controlled study with analysis of platelet number and growth factor levels. J Am Acad Dermatol. 2019; 80: 694-700.

39. Chrudinová M, Žáková L, Marek A, Socha O, Buděšínský M, Hubálek M, et al. A versatile insulin analog with high potency for both insulin and insulin-like growth factor 1 receptors: Structural implications for receptor binding. J Biol Chem. 2018; 293: 16818-16829.

40. Su HY, Hickford JG, Bickerstaffe R, Palmer BR. Insulin-like growth factor 1 and hair growth. Dermatol Online J 1999; 5: 1-6.

41. Surendiran A, Sandhiya S, Pradhan SC, Adirhat C. Novel applications of nanotechnology in medicine. Indian J Med Res. 2009; 130: 689-701.